Stockreport

PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer

PDS Biotechnology Corporation  (PDSB) 
Last pds biotechnology corporation earnings: 11/7 06:00 am Check Earnings Report
PDF 30 month median overall survival (OS); median OS independent of patient CPS score ORR 34% (CPS=1); 48% (CPS=20) Phase 3 registrational trial planned to initiate in 202 [Read more]